Center for Substance Abuse Prevention; Notice of Meeting, 24833 [05-9375]

Download as PDF Federal Register / Vol. 70, No. 90 / Wednesday, May 11, 2005 / Notices disorders. Dyslipidemic and vascular disorders amenable to treatment with the isolated multi-domain peptides include, but are not limited to, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, HDL deficiency, apoA-I deficiency, coronary artery disease, atherosclerosis, thrombotic stroke, peripheral vascular disease, restenosis, acute coronary syndrome, and reperfusion myocardial injury. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 4, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–9394 Filed 5–10–05; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention; Notice of Meeting Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) Drug Testing Advisory Board on June 1– 2, 2005. A portion of the meeting will be open and will include a roll call, general announcements, a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, and a Nuclear Regulatory Commission drug testing program update. Attendance by the public will be limited to space available. Public comments are welcome. Please VerDate jul<14>2003 16:48 May 10, 2005 Jkt 205001 communicate with the individual listed below as contact to make arrangements to comment or to request special accommodations for persons with disabilities. The Board will also meet to develop the analytical and administrative policies for the final revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Program that were published as proposed revisions in the Federal Register on April 13, 2004 (69 FR 19673). The submissions from 285 commenters have been made available to the public on the Web site http://workplace.samhsa.gov. This meeting will be conducted in closed session since discussing such public comments in open session and then developing the policies will significantly frustrate the Department’s ability to develop the final notice of revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The HHS Office of General Counsel made the determination that such matters are protected by exemption 9(B) of section 552b(c) of title 5 U.S.C. and therefore may be closed to the public. To facilitate entering the building for the open session, public attendees are required to contact Mrs. Giselle Hersh, Division of Workplace Programs, 1 Choke Cherry Road, Room 2–1042, Rockville, MD 20857, 240–276–2605 (telephone) or by e-mail to Giselle.Hersh@samhsa.hhs.gov. Substantive program information and a roster of Board members may be obtained by accessing the SAMHSA workplace Web site (http:// workplace.samhsa.gov) or communicating with the contact whose name and telephone number are listed below. The transcript for the open session will be available on the SAMHSA workplace website as soon as possible after the meeting. Committee Name: Substance Abuse and Mental Health Services Administration Drug Testing Advisory Board. Meeting Date: June 1–2, 2005. Place: SAMHSA Building, Sugarloaf Room, 1 Choke Cherry Road, Rockville, Maryland 20850. Type: Open: June 1, 2005; 8:30 a.m.–9:30 a.m. Closed: June 1, 2005; 9:30 a.m.–4:30 p.m. Closed: June 2, 2005; 8:30 a.m.–4:30 p.m. Contact: Donna M. Bush, Ph.D., Executive Secretary, 1 Choke Cherry Road, Room 2– 1033, Rockville, Maryland 20857, 240–276– 2600 (telephone) and 240–276–2610 (fax), Email: Donna.Bush@samhsa.hhs.gov. PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 24833 Dated: May 5, 2005. Toian Vaughn, Committee Management Officer, SAMHSA. [FR Doc. 05–9375 Filed 5–10–05; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration (SAMHSA) Notice of a Meeting Pursuant to Pub. L. 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) National Advisory Council in June 2005. The SAMHSA National Advisory Council will meet in an open session June 27 from 9 a.m. to 12:15 p.m., in San Diego, California. The meeting will include the SAMHSA Administrator’s Report, discussions concerning issues on SAMHSA’s appropriation and budget, and discussions on current administrative, legislative and program developments. The SAMHSA Council meeting will coincide with the Indian Health Services/SAMHSA Behavioral Health Conference which will be held on June 28 through June 30 in San Diego. Attendance by the public at the SAMHSA Council meeting will be limited to space available. Public comments are welcome. Please communicate with the individual listed as contact below to make arrangements to comment or to request special accommodations for persons with disabilities. Substantive program information, a summary of the meeting, and a roster of Council members may be obtained as soon as possible after the meeting, either by accessing the SAMHSA Council Web site, http://www.samhsa.gov/council/ council, or by communicating with the contact whose name and telephone number are listed below. The transcript for the meeting will also be available on the SAMHSA Council Web site within three weeks after the meeting. Committee Name: Substance Abuse and Mental Health Services Administration National Advisory Council. Date/Time: Monday, June 27, 2005, 9 a.m. to 12:15 p.m. (Open). Place: Hyatt Regency Islandia Hotel and Marina, Islands Ballroom, 1441 Quivira Road, San Diego, California 92109. Contact: Toian Vaughn, Executive Secretary, 1 Choke Cherry Road, Room 8– 1089, Rockville, Maryland 20857, Telephone: (240) 276–2307; FAX: (240) 276–2252 and Email: toian.vaughn@samhsa.hhs.gov. E:\FR\FM\11MYN1.SGM 11MYN1

Agencies

[Federal Register Volume 70, Number 90 (Wednesday, May 11, 2005)]
[Notices]
[Page 24833]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-9375]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Prevention; Notice of Meeting

    Pursuant to Pub. L. 92-463, notice is hereby given of the meeting 
of the Substance Abuse and Mental Health Services Administration 
(SAMHSA) Drug Testing Advisory Board on June 1-2, 2005.
    A portion of the meeting will be open and will include a roll call, 
general announcements, a Department of Health and Human Services drug 
testing program update, a Department of Transportation drug testing 
program update, and a Nuclear Regulatory Commission drug testing 
program update.
    Attendance by the public will be limited to space available. Public 
comments are welcome. Please communicate with the individual listed 
below as contact to make arrangements to comment or to request special 
accommodations for persons with disabilities.
    The Board will also meet to develop the analytical and 
administrative policies for the final revisions to the Mandatory 
Guidelines for Federal Workplace Drug Testing Program that were 
published as proposed revisions in the Federal Register on April 13, 
2004 (69 FR 19673). The submissions from 285 commenters have been made 
available to the public on the Web site http://workplace.samhsa.gov. 
This meeting will be conducted in closed session since discussing such 
public comments in open session and then developing the policies will 
significantly frustrate the Department's ability to develop the final 
notice of revisions to the Mandatory Guidelines for Federal Workplace 
Drug Testing Programs. The HHS Office of General Counsel made the 
determination that such matters are protected by exemption 9(B) of 
section 552b(c) of title 5 U.S.C. and therefore may be closed to the 
public.
    To facilitate entering the building for the open session, public 
attendees are required to contact Mrs. Giselle Hersh, Division of 
Workplace Programs, 1 Choke Cherry Road, Room 2-1042, Rockville, MD 
20857, 240-276-2605 (telephone) or by e-mail to 
Giselle.Hersh@samhsa.hhs.gov.
    Substantive program information and a roster of Board members may 
be obtained by accessing the SAMHSA workplace Web site (http://
workplace.samhsa.gov) or communicating with the contact whose name and 
telephone number are listed below. The transcript for the open session 
will be available on the SAMHSA workplace website as soon as possible 
after the meeting.

    Committee Name: Substance Abuse and Mental Health Services 
Administration Drug Testing Advisory Board.
    Meeting Date: June 1-2, 2005.
    Place: SAMHSA Building, Sugarloaf Room, 1 Choke Cherry Road, 
Rockville, Maryland 20850.
    Type:

Open: June 1, 2005; 8:30 a.m.-9:30 a.m.
Closed: June 1, 2005; 9:30 a.m.-4:30 p.m.
Closed: June 2, 2005; 8:30 a.m.-4:30 p.m.

    Contact: Donna M. Bush, Ph.D., Executive Secretary, 1 Choke 
Cherry Road, Room 2-1033, Rockville, Maryland 20857, 240-276-2600 
(telephone) and 240-276-2610 (fax), E-mail: 
Donna.Bush@samhsa.hhs.gov.

    Dated: May 5, 2005.
Toian Vaughn,
Committee Management Officer, SAMHSA.
[FR Doc. 05-9375 Filed 5-10-05; 8:45 am]
BILLING CODE 4162-20-P